IntRoduCtIon
T he introduction of intravitreal injections in ophthalmology has revolutionized the treatment of ophthalmic disease. Intravitreal injections have allowed for a high concentration of pharmaceuticals to be instilled at the site of treatment with minimal systemic side effects. Yet, there are numerous local side effects which have yet to be addressed with current day therapeutics. One of the most common side effects of intravitreal therapy is elevated intraocular pressure, both transient and sustained [1] [2] [3] [4] [5] . Numerous studies [6] [7] [8] have undertaken the task of attempting to decrease the intraocular pressure pre-injection by using anti-hypertensive ocular drops without success. In this case series, the authors investigate the safety and efficacy of a therapeutic anterior chamber paracentesis following an intravitreal injection to decrease the time of elevated intraocular pressure and prevent unwanted side effects related to increased intraocular pressure.
MEtHodS
This study is a retrospective analysis approved by the local institutional review board and was conducted in accordance with the Declaration of Helsinki for research in human subjects. The study reviewed the records of all patients that received a therapeutic anterior chamber paracentesis following an intravitreal injection of either bevacizumab or preservativefree triamcinolone acetonide (Figure 1 ). The patients that were included were those receiving an intravitreal injection with a history of ocular hypertension, primary or secondary open angle glaucoma, or sustained intraocular pressure following a previous injection who presented to a private retina practice over a period of 3y.
RESultS and dISCuSSIon
Of 1661 anterior chamber paracentesis procedures were performed ( Figure 1 . For this reason, the authors have decided that an immediate anterior chamber paracentesis will alleviate this early peak in pressure as the likely mechanism is an increase in volume inside the globe. They all showed that the majority of patients' intraocular pressures returned to the normal range within 30min to one hour and remained at that level for the following week [1] [2] [3] [4] [5] . Antivascular endothelial growth factor injections have previously been thought to only cause a transient elevation in intraocular pressure due to a direct intraocular volume increase [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , though there have been numerous cases [11] [12] [13] [14] showed sustained elevated pressure with intravitreal ranibizumab injections. Intravitreal steroids, on the other hand, have been known to cause both transient elevation as well as sustained elevation of the intraocular pressure. This sustained elevation in intraocular pressure is likely a result of increased outflow resistance [15] .
This can cause glaucomatous damage by decreasing the ocular perfusion pressure (mean arterial pressure-intraocular pressure) [1, 16] , as well as retinal vein and/or artery occlusion by direct compression [17] [18] [19] . Multiple randomized controlled trials have attempted to prevent this rapid rise in intraocular pressure with no success [6] [7] [8] .
Performing an anterior chamber paracentesis following injection causes a transient decrease in intraocular pressure. Normal production of aqueous humor can be as much as 3.0 μL/min [20] . At this rate, it should take longer than the hour that it normally takes for the intraocular pressure to return to normal physiologic levels after an anterior chamber paracentesis. Successful performance of this procedure leads to minimal amount of time, less than 5s, of dangerously elevated intraocular pressure. This decreases the likelihood of glaucomatous damage [21] by maintaining physiologic ocular perfusion, and retinal vein and artery occlusion by decreasing the time of increased pressure on the vessels. There is always the concern of iatrogenic events following any invasive procedure. The likely events include post-operative endophthalmitis, penetration of the crystalline lens in phakic patients, and wound leak. Although there were no cases of any intraoperative or postoperative complications, it is of the utmost importance to follow current day guidelines to prevent a septic work environment and have a physician experienced in intraocular injections performing these procedures to prevent any unwanted side effects of the procedure. We propose that performing an anterior chamber paracentesis immediately following an intravitreal injection for patients at risk for local side effects such as ocular hypertension, glaucoma, and retinal vein and artery occlusion is a safe and effective procedure. This procedure is not only effective in decreasing the time of elevated intraocular pressure and preventing damage to ocular structures, but it is safe and quick as well. As these patients are already dealing with sight threatening conditions, it is comforting to be able to provide an extra procedure to prevent complications to this sight restoring procedure. Future studies are needed to understand the long term and short term causation and effects of elevated intraocular pressure and determine if a concomitant anterior chamber paracentesis is, in fact, the proper way to prevent intraocular damage from elevated pressures. 
